LEXINGTON, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today provided a corporate update and reported financial results for the first quarter 2022.
Read more at globenewswire.com
Agenus Corporate Update and First Quarter 2022 Financial Report
Provided By Globe Newswire - Last update: May 10, 2022
Article Mentions:
